Reduced expression of the antigen processing machinery components TAP2, LMP2, and LMP7 in tonsillar and base of tongue cancer and implications for clinical outcome

Translational Oncology

Volumn 8, Issue 1, 2015, Pages 10-17

  Tertipis, Nikolaos ^a   Haeggblom, Linnea ^a   Grün, Nathalie ^a   Nordfors, Cecilia ^a   Näsman, Anders ^a   Dalianis, Tina ^a   Ramqvist, Torbjörn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; LMP2 PROTEIN; LMP7 PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TONGUE CANCER; TONSIL CANCER; TUMOR GROWTH;

EID: 84925849287     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.11.002     Document Type: Article

References (43)

1. Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, and Munck-Wikland E (2010). The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 126, 2879–2884
2. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, and Gillison ML (2013). Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31, 4550–4559
3. Chaturvedi AK, Engels EA, Anderson WF, and Gillison ML (2008). Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26, 612–619
4. Dalianis T (2014). Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int J Oncol 44, 1799–1805
5. Ernster JA, Sciotto CG, O'Brien MM, Finch JL, Robinson LJ, Willson T, and Mathews M (2007). Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 117, 2115–2128
6. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund- Richter S, Marklund L, Romanitan M, and Lindquist D, et al (2009). Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 124, 150–156
7. Ramqvist T and Dalianis T (2010). Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 16, 1671–1677
8. IARC (2007). Human Papillomaviruses. Lyon, France: WHO
9. Attner P, Nasman A, Du J, Hammarstedt L, Ramqvist T, Lindholm J, Munck- Wikland E, Dalianis T, and Marklund L (2012). Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer 131, 1124–1130
10. Dahlstrand H, Dahlgren L, Lindquist D, Munck-Wikland E, and Dalianis T (2004). Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor for clinical outcome. Anticancer Res 24, 1829–1835
11. Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J, Onelov L, Ramqvist T, Ye W, and Munck-Wikland E, et al (2007). Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1, 350–355
12. Chaturvedi AK (2012). Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 6(Suppl. 1), S16–S24
13. Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, and Ramqvist T (2012). Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 7, e38711
14. Nordfors C, Grun N, Tertipis N, Ahrlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund L, and Munck-Wikland E, et al (2013). CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 49, 2522–2530
15. Nasman A, Andersson E, Nordfors C, Grun N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T, and Ramqvist T (2013).MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 132, 72–81
16. Nasman A, Andersson E, Marklund L, Tertipis N, Hammarstedt-Nordenvall L, Attner P, Nyberg T, Masucci GV, Munck-Wikland E, and Ramqvist T, et al (2013). HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLoS One 8, e77025
17. Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, and Harabuchi Y (2010). HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 23, 933–939
18. Campoli M and Ferrone S (2008). HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27, 5869–5885
19. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, de Weger R, and Tilanus M (1999). HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 54, 235–245
20. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, and Garrido F (2002). Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51, 389–396
21. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, and Seliger B (2005). Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11, 2552–2560
22. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, and Ferrone S (2006). HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66, 9281–9289
23. Owen BA and Pease LR (1999). TAP association influences the conformation of nascent MHC class I molecules. J Immunol 162, 4677–4684
24. York IA and Rock KL (1996). Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14, 369–396
25. Ebstein F, Kloetzel PM, Kruger E, and Seifert U (2012). Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci 69, 2543–2558
26. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, and Fleuren GJ (2008). Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57, 197–206
27. Tertipis N, Haeggblom L, Nordfors C, Grun N, Nasman A, Vlastos A, Dalianis T, and Ramqvist T (2014). Correlation of LMP10 expression and clinical outcome in Human Papillomavirus (HPV) positive and HPV-Negative tonsillar and base of tongue cancer. PLoS One 9, e95624
28. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, and Dalianis T, et al (2006). Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119, 2620–2623
29. Team RC (2013). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; [Available from: http://www.r-project.org/]
30. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, and Frierson Jr HF (2010). Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 59, 465–472
31. Kageshita T, Hirai S, Ono T, Hicklin DJ, and Ferrone S (1999). Downregulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154, 745–754
32. Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, and Dosaka-Akita H, et al (2012). Downregulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 40, 965–974
33. Seliger B (2012). Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 61, 249–254
34. Frentzel S, Kuhn-Hartmann I, Gernold M, Gott P, Seelig A, and Kloetzel PM (1993). The major-histocompatibility-complex-encoded beta-type proteasome subunits LMP2 and LMP7. Evidence that LMP2 and LMP7 are synthesized as proproteins and that cellular levels of both mRNA and LMP-containing 20S proteasomes are differentially regulated. Eur J Biochem 216, 119–126
35. Beck S, Kelly A, Radley E, Khurshid F, Alderton RP, and Trowsdale J (1992). DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol 228, 433–441
36. Proffitt JA and Blair GE (1997). The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells. FEBS Lett 400, 141–144
37. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, and Ehrlich R (1996). LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183, 499–514
38. Larsen F, Solheim J, Kristensen T, Kolsto AB, and Prydz H (1993). A tight cluster of five unrelated human genes on chromosome 16q22.1. Hum Mol Genet 2, 1589–1595
39. Nandi D, Jiang H, and Monaco JJ (1996). Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol 156, 2361–2364
40. Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Della Beffa C, Ferrone S, and Bollo E (2012). MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. Transl Oncol 5, 48–55
41. Georgopoulos NT, Proffitt JL, and Blair GE (2000). Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19, 4930–4935
42. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, and Boon T, et al (2000). Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107–117
43. Nasman A, Nordfors C, Grun N, Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D, and Dalianis T (2013). Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med 2, 507–518.